Hemorrhagic Shock Treatment Market

Hemorrhagic shock is a condition resulting in tissue perfusion and inadequate delivery of oxygen and nutrients to cells. A traumatic injury can cause hemorrhagic shock if the bleeding does not stop immediately. The primary treatment for hemorrhagic shock is immediate control of the source of bleeding and fluid replacement. In CHS (controlled hemorrhagic shock), fluid replacement is prescribed to normalize hemodynamic parameters when the source of bleeding is stopped. Hemorrhagic shock is a rare condition that occurs in many gynecological or obstetric situations. In this condition, decreased blood volume results in sympathetic compensation with tachycardia, peripheral vasoconstriction, and increased myocardial contractility. This can increase the oxygen demand of the heart muscle.

Market Dynamics

With a broader understanding of the pathophysiology of hemorrhagic shock, treatment in trauma has expanded from a simple massive transfusion method to a more comprehensive management strategy of damage control resuscitation. For instance, September 1, 2022, VirTech developed a hemoglobin-based solution with blood-like oxygen carrying capacity that caught the attention of the Pentagon, the US Department of Defense. This division of the US government made a contribution of US$ 13 million that is driving toward the clinical research phase of the project. The objective is to use the product to prevent hemorrhagic shock in trauma patients and to give better survival to organs donated for transplantation.The Pentagon was interested in the possibility of the solution preventing hemorrhagic shock, a problem that affects military personnel in combat or civilians who suffer trauma, such as automobile accidents. In these cases, hemorrhagic shock is usually the main cause of death, as there is often no time for a transfusion. Research carried out so far shows that the solution, injected into the body as a temporary blood substitute, considerably increases the time available for the victim to arrive at a hospital for transfusion.

Key features of the study:                                                                                                               

• This report provides an in-depth analysis of the global hemorrhagic shock treatment market and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global hemorrhagic shock treatment market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Biomedica Management Corporation, NuvOxPharma LLC, Leading BioSciences, Inc, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Johnson & Johnson Services Inc, AstraZeneca, Daiichi Sankyo Company, Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, ZydusCadila, Amneal Pharmaceuticals LLC.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global hemorrhagic shock treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hemorrhagic shock treatment market.

Detailed Segmentation:

• Global Hemorrhagic Shock Treatment Market, By Drug Type:
  • NVX-408
  • YW-356
  • LB-1148
  • Neutrolide
  • Others
• Global Hemorrhagic Shock Treatment Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels
• Global Hemorrhagic Shock Treatment Market, By Region:
  • North America
    
    • U.S.
    • Canada
  • Latin America
    
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
  • Biomedica Management Corporation
  • NuvOxPharma LLC
  • Leading BioSciences, Inc
  • F. Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim International GmbH
  • Johnson & Johnson Services Inc
  • AstraZeneca
  • Daiichi Sankyo Company, Limited
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • ZydusCadila
  • Amneal Pharmaceuticals LLC